Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Senior Reporter

Eli Lilly has tapped another gene editing partner, this time looking to go after a large patient population in the cardiovascular space with the help …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing